3DMed Diagnostics Raised CNY 1.5 Billion in Equity Round 3DMed Diagnostics Donates Medical Supplies to Support COVID-19 Fight in Cambodia

2021-11-12 16:20

3DMed Diagnostics, a leading company in molecular diagnostic platforms, has recently announced the completion of a new equity financing round which raised a total of CNY 1.5 billion. This marks the second round of independent financing carried out by 3DMed Diagnostics after gaining independence from the 3DMed Group. Prior to this, 3DMed Diagnostics has received CNY 280 million in its first round of financing following the spin-off in 2019, while 3DMed Novel Drug has raised a total of US$140 million in its initial financing round after its spin-off a few days ago. Led by CPE, this round of financing attracted investments from a subsidiary of CICC Capital, Jemincare, CTS Funds, Pudong Kechuang, Haier Biomedical, Ruiyi Investment, and Lanshang Capital. In addition, Luxin Venture Capital, Shandong Transportation Industry Development Fund, and Sangel Venture Capital raised their existing investments. CEC Capital served as the exclusive financial advisor in this round of financing.
 
Following years of persistent efforts, 3DMed Diagnostics has established itself as one of the leaders in the field of precision diagnosis in China, as well as a trusted provider of third-party testing services, IVD devices, and reagents. The company offers solutions in tumor management (from early diagnosis, companion diagnosis to dynamic monitoring), and is working on a series of products in the field of microbiological diagnosis. Some highlights include:
 
1) Early diagnosis kit for ovarian cancer based on its independent exosomal marker development platform. The kit has entered clinical trials for registration.

2) Fully automated data analysis system developed in 2018 to perform companion diagnostics and dynamic monitoring. In 2019, ANDiS400, the fully automated closed library preparation system developed by the company was approved by the National Medical Products Administration (NMPA) for the market. At present, the company has formed a series of R&D pipelines for fully automated platforms, and completed the registration for the development of the pipelines of automated companion diagnostics and dynamic monitoring products. Looking forward, the successive launch of this product pipeline will ameliorate the problem that NGS technology cannot be scaled up in domestic oncology hospitals because of its complexity. Through extensive involvement in the research and development of precision diagnosis, 3DMed Diagnostics has successfully developed its fully automated protein and molecular diagnostic products, and established a multi-disciplinary R&D team with backgrounds in equipment engineering, electrical engineering, life sciences, materials, and data analysis. This lays a solid foundation for the company's mission and vision of making precision medicine accessible to patients anytime, anywhere.
 
Dr. Lei Xiong, Chairman and CEO of 3DMed Diagnostics, thanked new and existing investors for putting their faith in the company, saying that, “Funds raised in this financing round will be mainly used for the research, development, and registration of equipment and reagent products in the field of precision diagnosis, including fully automated NGS assembly line equipment, molecular diagnostic equipment, multiple precision diagnostic IVD products, AI-based automated diagnostic products, and exosome platform-based early diagnostic IVD products. In addition, the funds will also be channeled towards the expansion of the commercialization team and overseas expansion."
 
CPE said, “With the approval of more precision therapies and targeted immune drugs, as well as the continuous emergence of new treatments, sequencing technology has bright prospects in the field of precision oncology. As the leader in the precision diagnosis of tumors, 3DMed Diagnostics has made an early entrance into the field of sequencing automation and now offers clinics with a full set of solutions based on sequencing technologies. This drives the expansion of relevant clinical applications, helping physicians select more accurate treatment plans, so as to prolong lives and improve the patients’ quality of life. We are honored to share this journey with Dr. Xiong Lei and his team in our concerted efforts to promote the development of precision therapies for cancer patients.”
 
The CICC Capital investment team added, “Precision medicine has always been an area of interest for CICC. As a vital connection between patients and treatments, precision diagnosis has great potential in terms of clinical application. We are optimistic about the advanced strategic approach of 3DMed Diagnostics in the field of automated NGS and its integrated solutions of closed equipment plus reagents and consumables. At the same time, we also feel reassured due to the experienced and efficient leadership, R&D and sales team, as well as the company’s outstanding track record of innovations. We have full confidence in the company's future development and are honored to be a part of this round of investment."
 
Mr. Zhou Zhijian, head of investment at Jemincare, commented, “As a pharmaceutical group specializing in therapies for cancer, cardio-cerebrovascular disease, and kidney disorders, etc., Jemincare has been ranked among the top ten in China's Top 100 Pharmaceutical Companies Chart for several years and has been selected as a well-reputated national undertaking by Xinhua News Agency. With the advent of the era of targeted therapy and immunotherapy, precision diagnosis has also ushered in a period of rapid development. Being a top company in China's tumor NGS detection industry, 3DMed Diagnostics definitely has certain first-mover advantages in the fields of exosomal-based early diagnosis and NGS-based tumor IVD. Jemincare feels upbeat about the development prospects of 3DMed Diagnosis in the field of precision diagnosis under the leadership of Dr. Lei Xiong, and looks forward to working hand in hand with the company to facilitate its growth!
 
Founding Partner of CTS Funds, Mr. Zhang Song, said, “The time has arrived for precision diagnosis. With its forward-looking approach in the field of precision diagnosis, 3DMed Diagnostics is an enterprise that is truly rooted in the needs of the industry and clinical applications. It offers solutions for clinical pain points through strong R&D, manufacturing, and commercialization capabilities. CTS Funds feels very positive about the development prospects of 3DMed Diagnostics in the field of clinical precision diagnosis, and will continue to lend the company support in terms of industrial resources and strategic development.”
 
Mdm. Fu Hongyan, Chairwoman of Pudong Kechuang, said “With our unwavering emphasis on life sciences, our firm has always provided innovative companies with multi-dimensional and high-quality support. They have grown into an industrial cluster reaching into various sub-fields, with their own advantages. Pudong Kechuang has a track record of active participation in the development of many such innovative companies, with investments in Fudan Zhangjiang, TellGen, Tasly, Investis Bio, and Peijia Medical, etc. We feel optimistic about the strong innovative R&D capabilities of 3DMed Diagnostics based on multiple technologies, as well as their achievements in the field of precision diagnosis. With our sights set on the future, Pudong Kechuang will further expand and strengthen our all-round support for 3DMed Diagnosis."
 
Mr. Ni Xiaowei, CEO of Haier Biomedical, said, “Haier Biomedical is a large ecological co-creation platform that strives to bring doctors and patients together, and comprehensive tumor treatment is one of the four major focuses of Haier Biomedical. Having been deeply involved in the field of precision diagnosis for many years, 3DMed Diagnostics leads the industry in R&D platform, as well as products and services for early tumor screening, companion diagnostics and rehabilitation dynamic monitoring. Its developments are perfectly in sync with Haier Biomedical's vision. As an investor in this round, I am very pleased to join hands with other shareholders to drive the further development of 3DMed Diagnostics. I believe that 3DMed Diagnostics will continue to create greater value for the world under the leadership of Dr. Xiong Lei and his team. Moving forward, Haier Biomedical will also actively explore possibilities of collaborations with 3DMed Diagnostics in the field of comprehensive tumor treatment, so as to deliver the best possible experience to cancer patients. “
 
Founding Partner of Ruiyi Investment, Mr. Deng Yuehui, said, “The application of NGS companion diagnostics and early tumor screening has seen a boom in recent years. As a pioneer in the field of precision oncology, 3DMed Diagnostics has huge potential for growth. With its position at the forefront of this field, 3DMed Diagnostics has experienced rapid growth under the leadership of Dr. Xiong Lei and his professional team. We believe that in helping Chinese cancer patients obtain more accurate treatment, 3DMed Diagnostics will become a leading company respected by both doctors and patients. Being new in the market, Ruiyi Investment is very fortunate to be an investor in such an outstanding company. We wish 3DMed Diagnostics, Dr. Lei Xiong and his team all our best!”
 
Chairman of Luxun VC, Mr. Chen Lei commented that, “As an angel investor, Luxin VC believes strongly in "growing with the company", and will continue to raise its investment in 3DMed Diagnostics. We are pleased to witness the company's growth in the field of precision oncology as well as its transformation into a leader in commercial implementation and technological innovation. We have no doubt that 3DMed Diagnostics will bring precision medicinal technologies to the masses in the future, thus helping more patients to benefit from such advancements.”
 
As the financial advisor in this financing round, Mr Li Gang, a partner at CEC Capital, said, “With itsyears of involvement in the field of molecular diagnostics, 3DMed Diagnostics has established three major research and development platforms, namely the automated NGS platform, exosome detection platform, and infectious disease detection platform. Having demonstrated progress in both IVD products and clinical testing, 3DMed Diagnostics is well-established as a leader in the field of precision molecular diagnostics. The participation of China's first-tier funds in this round reflects the recognition of its leading position in the diagnostics field, as well as its many years of commercial experience. CEC Capital has worked with 3DMed Diagnostics for several years, and has witnessed the continuous development and growth of the company. "We are very honored to be a part of this round of financing, and we look forward to more of its milestones in this industry, so as to help patients in China and around the world."